Compare Stocks: OGN, PRGO, ACAD, and AXSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$18.23 +0.5%	$21.97	$15.85 ▼ $30.96	$3.13B	0.87	1.82 million shs	111,976 shs
AXSM Axsome Therapeutics	$139.13 -3.6%	$172.78	$123.00 ▼ $260.19	$7.32B	0.86	791,322 shs	108,461 shs
OGN Organon & Co.	$13.90 0.0%	$13.76	$5.69 ▼ $13.90	$3.65B	1.53	4.92 million shs	120,531 shs
PRGO Perrigo	$16.33 +0.9%	$15.13	$9.23 ▼ $17.02	$2.26B	0.71	3.00 million shs	53,051 shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-1.25%	-14.60%	-2.58%	-35.76%	-24.82%
AXSM Axsome Therapeutics	-3.26%	+11.22%	-7.64%	-32.43%	+2.49%
OGN Organon & Co.	+0.14%	+0.59%	+0.87%	+1.31%	+80.34%
PRGO Perrigo	-2.18%	+3.31%	+5.59%	+24.46%	+14.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$18.23 +0.5%	$21.97	$15.85 ▼ $30.96	$3.13B	0.87	1.82 million shs	111,976 shs
AXSM Axsome Therapeutics	$139.13 -3.6%	$172.78	$123.00 ▼ $260.19	$7.32B	0.86	791,322 shs	108,461 shs
OGN Organon & Co.	$13.90 0.0%	$13.76	$5.69 ▼ $13.90	$3.65B	1.53	4.92 million shs	120,531 shs
PRGO Perrigo	$16.33 +0.9%	$15.13	$9.23 ▼ $17.02	$2.26B	0.71	3.00 million shs	53,051 shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-1.25%	-14.60%	-2.58%	-35.76%	-24.82%
AXSM Axsome Therapeutics	-3.26%	+11.22%	-7.64%	-32.43%	+2.49%
OGN Organon & Co.	+0.14%	+0.59%	+0.87%	+1.31%	+80.34%
PRGO Perrigo	-2.18%	+3.31%	+5.59%	+24.46%	+14.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.72	Moderate Buy	$31.55	73.12% Upside
AXSM Axsome Therapeutics	2.86	Moderate Buy	$267.58	92.32% Upside
OGN Organon & Co.	1.80	Reduce	$12.00	-13.64% Downside
PRGO Perrigo	1.83	Reduce	$18.50	13.29% Upside

Current Analyst Ratings Breakdown

Latest OGN, PRGO, ACAD, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/10/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C+)
11/6/2026	ACAD ACADIA Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$36.00 ➝ $38.00
11/5/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$36.00 ➝ $38.00
11/4/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$284.00 ➝ $272.00
11/3/2026	PRGO Perrigo	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
11/3/2026	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
11/3/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$256.00 ➝ $239.00
11/3/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$247.00 ➝ $249.00
11/3/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$295.00 ➝ $273.00
11/3/2026	AXSM Axsome Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$275.00 ➝ $250.00
11/3/2026	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$246.00 ➝ $220.00

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	2.94	$0.88 per share	20.71	$8.03 per share	2.27
AXSM Axsome Therapeutics	$638.50M	11.46	N/A	N/A	$2.00 per share	69.57
OGN Organon & Co.	$6.22B	0.59	$5.79 per share	2.40	$4.54 per share	3.06
PRGO Perrigo	$4.25B	0.53	$5.22 per share	3.13	$17.58 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.11	8.58	16.88	N/A	30.13%	8.90%	6.86%	N/A
AXSM Axsome Therapeutics	-$183.17M	-$3.06	N/A	38.01	N/A	-18.18%	-198.73%	-22.03%	N/A
OGN Organon & Co.	$187M	$0.76	18.28	4.05	1.28	3.49%	82.06%	6.03%	N/A
PRGO Perrigo	-$1.43B	-$12.76	N/A	7.36	1.78	-43.27%	12.39%	4.07%	N/A

Latest OGN, PRGO, ACAD, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	ACAD ACADIA Pharmaceuticals	$0.1992	$0.31	+$0.1108	$0.31	$332.58 million	$342.30 million
11/4/2026	Q3 2026	PRGO Perrigo	$0.5110	$0.60	+$0.0890	-$0.20	$984.80 million	$988.60 million
11/2/2026	Q3 2026	AXSM Axsome Therapeutics	-$0.6343	-$0.25	+$0.3843	-$0.25	$249.19 million	$259.69 million
10/30/2026	Q3 2026	OGN Organon & Co.	$0.88	$0.94	+$0.06	$0.60	$1.58 billion	$1.57 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.53%	N/A
PRGO Perrigo	$1.16	7.10%	+5.21%	N/A	23 Years

Latest OGN, PRGO, ACAD, and AXSM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/29/2026	PRGO Perrigo	quarterly	$0.29	7.32%	11/27/2026	11/27/2026	12/15/2026
10/30/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	11/9/2026	11/9/2026	12/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.82	3.70
AXSM Axsome Therapeutics	1.21	1.42	1.34
OGN Organon & Co.	7.11	2.02	1.51
PRGO Perrigo	1.35	2.35	1.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AXSM Axsome Therapeutics	81.49%
OGN Organon & Co.	77.43%
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
AXSM Axsome Therapeutics	20.60%
OGN Organon & Co.	1.62%
PRGO Perrigo	0.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	798	172.83 million	127.55 million	Optionable
AXSM Axsome Therapeutics	925	52.60 million	41.76 million	Optionable
OGN Organon & Co.	10,000	262.62 million	258.37 million	Optionable
PRGO Perrigo	8,100	138.80 million	138.25 million	Optionable

OGN, PRGO, ACAD, and AXSM Headlines

Recent News About These Companies

Perrigo Company plc (NYSE:PRGO) Stock Now Rated "Reduce" by Wall Street Analysts

November 12 at 3:15 AM | americanbankingnews.com

Perrigo to Attend the Jefferies Miami Consumer Conference

November 11 at 8:30 AM | prnewswire.com

Perrigo (NYSE:PRGO) Hits New 12-Month High - Here's Why

November 9, 2026 | marketbeat.com

Perrigo Q3 Earnings Call Highlights

November 7, 2026 | marketbeat.com

How Investors May Respond To Perrigo (PRGO) Weak 2026 Outlook

November 7, 2026 | finance.yahoo.com

Is Perrigo (PRGO) Undervalued After Its 2026 Sales Guidance Cut?

November 7, 2026 | finance.yahoo.com

Perrigo Company plc (PRGO) - What Are Analysts Saying About This Stock?

November 7, 2026 | marketbeat.com

Perrigo: 3 Key Takeaways for Long-Term Investors

November 6, 2026 | fool.com

Canaccord Genuity Reaffirms Their Buy Rating on Perrigo Company (PRGO)

November 6, 2026 | theglobeandmail.com

Perrigo Company plc (PRGO) Q3 2026 Earnings Call Transcript

November 4, 2026 | seekingalpha.com

Perrigo (PRGO) Q3 2026 Earnings Call Transcript

November 4, 2026 | finance.yahoo.com

Perrigo (NYSE:PRGO) Issues Earnings Results

November 4, 2026 | marketbeat.com

Perrigo Company plc 2026 Q3 - Results - Earnings Call Presentation

November 4, 2026 | seekingalpha.com

Perrigo Company Slips To Loss In Q3

November 4, 2026 | rttnews.com

Earnings Flash (PRGO) Perrigo Posts Q3 Adjusted EPS $0.60 per Share, vs. FactSet Est of $0.51

November 4, 2026 | marketscreener.comM

Perrigo Company plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 26, 2026

November 4, 2026 | marketscreener.comM

Perrigo (PRGO) Reports Q3 Earnings: What Key Metrics Have to Say

November 4, 2026 | zacks.com

Perrigo Q3 2026 Earnings Call Transcript

November 4, 2026 | benzinga.com

Perrigo (PRGO) Surpasses Q3 Earnings Estimates

November 4, 2026 | zacks.com

Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

November 4, 2026 | prnewswire.com

Perrigo (PRGO) Rebounds as Bad News Turns Less Bad

November 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN, PRGO, ACAD, and AXSM Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$18.23 +0.09 (+0.47%)

As of 10:37 AM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Axsome Therapeutics NASDAQ:AXSM

$139.13 -5.24 (-3.63%)

As of 10:37 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Organon & Co. NYSE:OGN

$13.90 -0.01 (-0.04%)

As of 10:37 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Perrigo NYSE:PRGO

$16.33 +0.15 (+0.93%)

As of 10:37 AM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OGN, PRGO, ACAD, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OGN, PRGO, ACAD, and AXSM Earnings

Compare Dividends

Latest OGN, PRGO, ACAD, and AXSM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OGN, PRGO, ACAD, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN, PRGO, ACAD, and AXSM Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Axsome Therapeutics NASDAQ:AXSM

Organon & Co. NYSE:OGN

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OGN, PRGO, ACAD, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OGN, PRGO, ACAD, and AXSM Earnings

Compare Dividends

Latest OGN, PRGO, ACAD, and AXSM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OGN, PRGO, ACAD, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN, PRGO, ACAD, and AXSM Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Axsome Therapeutics NASDAQ:AXSM

Organon & Co. NYSE:OGN

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools